Association for Molecular Pathology (AMP)’s Post

Introducing Bio-Rad's Celselect Slides™ Validated Antibodies for rare cell & circulating tumor cell (CTC) enumeration, in tandem with Celselect Slides Enumeration Stain Kits. Specifically designed for detection of CTC surface markers, these antibodies enhance tumor heterogeneity and disease progression studies. Our Genesis Cell Isolation System captures diverse CTCs for downstream analysis or on-slide immunostaining, facilitating enumeration & identification. Learn more at https://ow.ly/jVHf50RwZE5 #CancerResearch

High quality tissue means high quality data. High quality data means access to the full molecular reality of cancer. A full picture of the cancer disease enables drug discovery programs that are more efficient and more likely to result in new treatments for cancer patients. https://lnkd.in/g9NprBCE

Interesting article in Wall Street Journal on Feb 2nd regarding new Galleri test by GRAIL which can detect tumors long before symptoms develop. The test is expensive today and not FDA approved, just as genetic testing was once out of range in cost for most Americans, and today saves many lives. The Galleri test has the potential to save lives through early detection for people who have a predisposition for cancer and doctors could recommend for patients over a certain age. The cost will come down as the test is improved, used and hopefully passed by Congress for a medicare cost for older Americans. We need every tool in our toolbox to prevent and save lives against cancer, and catching this disease early in every form is paramount. #cscde #cancersupport #cancerawareness #mentalhealthawareness https://lnkd.in/dHGPZiNi

July is Sarcoma Awareness Month. Sarcoma is very rare, and much more research needs to be done to fully understand how these cancers develop, how best to diagnose and treat them, and improve patient outcomes. Omico is currently conducting an initiative called PrOSPeCT which includes providing comprehensive genomic profiling, at no cost, for people with advanced, incurable or poor prognosis cancers in Australia.  If you are a patient living with sarcoma in Australia, you could be eligible for this initiative. If you want to learn more about comprehensive genomic profiling to see how it can potentially help you, join our upcoming free patient webinar. Register here: https://lnkd.in/g5US2-9H You can also click here to view our patient information booklet: https://lnkd.in/g_SK5SYn To learn more about PrOSPeCT and Omico, please visit: www.omico.com Share this post to help spread awareness.🙏 #Sarcoma #SarcomaAwareness #CancerMeetsItsMatch #Omico #GenomicProfiling #sarcomaawarenessmonth24 #ANZSA

A “danger close” mission is one where friendly forces are put in jeopardy because of their proximity to the line of fire. Another “danger close” mission involves the concomitant administration of a checkpoint inhibitor with the EpicentRx lead oncolytic adenovirus, AdAPT-001. Because #AdAPT001 expresses the anti-immunosuppressive #TGFβ trap and lyses tumor cells, it makes previously “cold” tumors “hot” and revs up the immune system to go on the attack, which supports the anticancer effects of checkpoint inhibitors even in patients that were previously resistant to them. Read more here: https://bit.ly/4dmNB32.

Do you know about FGFR2b in #GastricCancer? This emerging biomarker is prevalent in 20% to 30% of people with an advanced form of this disease. Because of its link to tumor growth, FGFR2b is a compelling 🎯 target for investigation. Learn more at https://amgen.ly/3ymnFVz

Meridian's Liquid Biopsy Urine DNA qPCR Mix is a glycerol-free, one-tube formulation compatible with all dual-label probe chemistries for the detection of genetic variants, such as single nucleotide variants (SNPs) and copy number variants. It is designed for fast, precise, and reproducible allelic discrimination and cluster separation, and is ideal for a number of applications including cancer biomarker detection, infectious disease testing, non-invasive prenatal testing and pharmacogenomics. Click here to learn more: https://ow.ly/Se2g50Tyuju #molecuardiagnostics #stds #genotyping#hpv#cervicalcancerscreening#urinetest

https://ow.ly/NWp750TnrjY Data from some abstracts presented at the ESMO Congress 2024 (Barcelona, 13–17 September) add to our knowledge of the role of liquid biopsy, and in particular of circulating tumour (ct) DNA, in early-stage disease.

In this study, real-world comprehensive genomic and immune profiling (CGIP) data, derived from testing many patients with NSCLC (>8,000) during their standard care, was utilized to look for differences in genomic alterations and immune activity in younger versus older patient tumors. Important differences in younger patient tumors was found, including higher frequency of genomic alterations in key NSCLC driver genes and less immune activity overall, especially when looking at male patient tumors. Taken together, the results show the value of CGIP for informing clinical treatment of younger patients with NSCLC and provides support for broader coverage of CGIP for younger patients. Learn more: https://lnkd.in/ehgcckqj

In this study, real-world comprehensive genomic and immune profiling (CGIP) data, derived from testing many patients with NSCLC (>8,000) during their standard care, was utilized to look for differences in genomic alterations and immune activity in younger versus older patient tumors. Important differences in younger patient tumors was found, including higher frequency of genomic alterations in key NSCLC driver genes and less immune activity overall, especially when looking at male patient tumors. Taken together, the results show the value of CGIP for informing clinical treatment of younger patients with NSCLC and provides support for broader coverage of CGIP for younger patients. Learn more: https://lnkd.in/e_NW_fiU